• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary therapy. >Epidemiology of Pulmonary Fibrosis: A Cohort Study Using Healthcare Data in Sweden
【24h】

Epidemiology of Pulmonary Fibrosis: A Cohort Study Using Healthcare Data in Sweden

机译：肺纤维化流行病学：一项使用瑞典医疗数据的队列研究

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionData on the epidemiology of idiopathic pulmonary fibrosis (IPF) in Sweden are lacking. This study estimates the incidence and prevalence of IPF in Sweden, and describes the demographic and clinical characteristics and the overall survival of patients with IPF. MethodsTwo cohorts were studied: a national cohort of 17,247 patients with pulmonary fibrosis (ICD-10 code J84.1 with no competing diagnosis) from the Swedish National Patient Register (cohort 1 [C1]); and an electronic medical record-based regional subset of C1 comprising 1755 patients having pulmonary fibrosis and a radiology procedure (C2). ResultsThe incidence of pulmonary fibrosis in C1 ranged from 10.4 to 15.4 cases per 100,000 population per year between 2001 and 2015. The prevalence increased from 15.4 to 68.0 cases per 100,000 population per year. Patients?≥?70?years and men had a higher incidence and prevalence of pulmonary fibrosis. Common comorbidities included respiratory infections and cardiovascular disorders. Approximately one-third of patients in each cohort were hospitalised with pulmonary fibrosis within a year of diagnosis. The median survival time from disease diagnosis was 2.6?years in C1 and 5.2?years in C2. Older patients had a higher risk of hospitalisation and mortality. Women had a better prognosis than men. ConclusionThis study underscores the importance of pulmonary fibrosis as a cause of respiratory-related morbidity and mortality in Sweden. The stable incidence and increasing prevalence over time suggests longer survival. The higher morbidity and mortality in older patients highlights the importance of early case detection, diagnosis and management for better prognosis. FundingF. Hoffmann-La Roche, Ltd./Genentech, Inc.
机译：简介缺乏瑞典特发性肺纤维化（IPF）流行病学数据。这项研究估计了瑞典IPF的发生率和患病率，并描述了IPF患者的人口统计学和临床​​特征以及总体生存率。方法研究了两个队列：来自瑞典国家患者登记簿（队列1 [C1]）的17247例肺纤维化患者（ICD-10代码J84.1，无竞争诊断）。以及C1的基于电子病历的区域子集，包括1755名患有肺纤维化和放射学程序（C2）的患者。结果2001年至2015年，C1的肺纤维化发生率从每年每100,000人口的10.4例到15.4例。患病率从每年每100,000人口的15.4例增加到68.0例。 ≥70岁的患者和男性的肺纤维化发生率和患病率较高。常见合并症包括呼吸道感染和心血管疾病。在诊断的一年内，每个队列中约有三分之一的患者因肺纤维化住院。疾病诊断的中位生存时间在C1为2.6年，在C2为5.2年。年龄较大的患者住院和死亡的风险较高。女性的预后比男性好。结论这项研究强调了肺纤维化作为瑞典与呼吸有关的发病率和死亡率的原因的重要性。随着时间的流逝，稳定的发病率和患病率的增加表明生存期更长。老年患者较高的发病率和死亡率突出了早期发现病例，诊断和治疗对改善预后的重要性。资金F.霍夫曼-拉罗什有限公司/ Genentech，Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号